Trials / Completed
CompletedNCT02314299
A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration
A Phase 1/2, Open-Label, Dose-Escalation, Single Center, Clinical Study of MTP-131 (Ocuvia™) Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration.
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Stealth BioTherapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1/2, open-label, dose-escalation clinical study, enrolling 21 subjects in one of the two treatment groups to determine the effects of topical ocular administration of low dose or high dose MTP-131 given twice a day in subjects with Diabetic Macular Edema and Age-Related Macular Degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MTP-131 |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2015-05-01
- Completion
- 2015-06-01
- First posted
- 2014-12-11
- Last updated
- 2015-10-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02314299. Inclusion in this directory is not an endorsement.